ArticleBritish journal of cancer2015
Risk factors and time to symptomatic presentation in leukaemia, lymphoma and myeloma.
Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis.BMJ open · 2018Pooled it
- Pathways to myeloproliferative neoplasm presentation and time to diagnosis: results from a cross-sectional study.BJGP open · 2025Article
- Article
- What causes delays in diagnosing blood cancers? A rapid review of the evidence.Primary health care research & development · 2023Review
- Low knowledge and awareness of monoclonal gammopathy of undetermined significance (MGUS) among general practitioners.BMC family practice · 2019Article
- Communication strategies for rare cancers: a systematic review protocol.Systematic reviews · 2019Article
- Disease-related factors affecting timely lymphoma diagnosis: a qualitative study exploring patient experiences.The British journal of general practice : the journal of the Royal College of General Practitioners · 2019Article
- What is the significance of monoclonal gammopathy of undetermined significance?Clinical medicine (London, England) · 2018Review
- Severe abdominal pain and diarrhea - unusual multiple myeloma presentation with a severe prognosis: a case report.Journal of medical case reports · 2018Article
- Article
- Symptom Signatures and Diagnostic Timeliness in Cancer Patients: A Review of Current Evidence.Neoplasia (New York, N.Y.) · 2018Review
- An observational study assessing peripheral neuropathy related to multiple myeloma.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2016Observational
- Post-sampling mortality and non-response patterns in the English Cancer Patient Experience Survey: Implications for epidemiological studies based on surveys of cancer patients.Cancer epidemiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundUK policy aims to improve cancer outcomes by promoting early diagnosis, which for many haematological malignancies is particularly challenging as the pathways leading to diagnosis can be difficult and prolonged.
methodsA survey about symptoms was sent to patients in England with acute leukaemia, chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), myeloma and non-Hodgkin lymphoma (NHL). Symptoms and barriers to first help seeking were examined for each subtype, along with the relative risk of waiting >3 months' time from symptom onset to first presentation to a doctor, controlling for age, sex and deprivation.
resultsOf the 785 respondents, 654 (83.3%) reported symptoms; most commonly for NHL (95%) and least commonly for CLL (67.9%). Some symptoms were frequent across diseases while others were more disease-specific. Overall, 16% of patients (n=114) waited >3 months before presentation; most often in CML (24%) and least in acute leukaemia (9%). Significant risk factors for >3 months to presentation were: night sweats (particularly CLL and NHL), thirst, abdominal pain/discomfort, looking pale (particularly acute leukaemias), and extreme fatigue/tiredness (particularly CML and NHL); and not realising symptom(s) were serious.
conclusionsThese findings demonstrate important differences by subtype, which should be considered in strategies promoting early presentation. Not realising the seriousness of some symptoms indicates a worrying lack of public awareness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.